期刊文献+

乙脑/登革2型嵌合病毒的构建

Construcion of a Chimeric Japanese Encephalits Virus/Dengue Virus-2
原文传递
导出
摘要 在乙脑病毒SA14-14-2株复制子载体pPartial△prM/E中克隆入DV2(Dengue virus serotype 2)的prM/E基因,构建乙脑/登革2型嵌合体克隆。将嵌合体克隆线性化后体外转录,获得的RNA转染BHK-21细胞,5~7d可观察到CPE。收获病毒上清液分别感染BHK-21细胞及C6/36细胞。接种于C6/36细胞中的嵌合病毒可使细胞出现CPE,RT-PCR、间接免疫荧光和Western blot检测显示:获得的嵌合病毒具有预期嵌合性核酸并能表达DV2的包膜蛋白,但不能在BHK-21细胞中传代培养。成功构建的乙脑/登革2型感染性克隆为进一步研究登革病毒疫苗奠定了基础。 The prM/E gene of DV2 was cloned into the JEV (SA14-14-2 strain) replicon vector which had been constructed previously, and the resulting recombinant plasmid was named pPartial△prM/E. The constructed chimeric clone was linearized and then was transcripted into RNA in vitro. The produced RNA was transfected into BHK-21 cells. Five to seven days later, CPE could be observed on the transfected BHK-21eells, and then the supernatant containing the chimeric virus was collected. The Supernatant was inoculated to BHK-1 cells and C6/36 cells, respectively. CPE could be observed about 4 days post the infection of C6/36cell with the chimeric virus. The results from RT-PCR, IFA, Western blot showed that the virus contained the chimeric RNA and the envelop protein of DV2. However, the chimeric virus could not be passaged in BHK-21 cell. The successful construction of the infectious clone JE/DEN-2 laid the basis for the further research of the DV vaccine.
出处 《病毒学报》 CAS CSCD 北大核心 2009年第3期185-189,共5页 Chinese Journal of Virology
基金 国家自然科学基金(30770087)
关键词 乙脑 登革 嵌合病毒 感染性克隆 Japanese encephalits virus Dengue Virus chimeric virus Infectious clone
  • 相关文献

参考文献8

  • 1Bray M, Men R, Lai C J. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge[J]. J Virol, 1991, 70: 4162- 4166.
  • 2Guirakhoo F, Weltzin R. , Chambers T J. , et al. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates[J]. J Virol, 2000, 74:5477-5485.
  • 3Guirakhoo F, Arroyo J, Pμgaehev K V, et al. Construction, Safety, and Immunogenicity in Nonhuman Primates of a Chimeric Yellow Fever-Dengue Virus Tetrava lent Vaccine[J]. J Virol, 2001, 75(16):7290-7304.
  • 4Guirakhoo F, Pbtgachev K, Zhang Z, et al. Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formμlations in Nonhuman Primates[J]. J Virol, 2004, 78(9) :4761-4775.
  • 5Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue vaccine[J]. Vaccine, 2000, Suppl 2:44- 47.
  • 6Butrapet S, Huang C Y, Pierro D J, et al. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5' noneoding region and nonstructural proteins 1 and 3 [J]. J Virol, 2000, 74(7):3011-3019.
  • 7Huang C Y, Butrapet S, Tsuchiya K R et al. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccinedevelopment[J]. J Virol, 2003, 77(21):11436- 11447.
  • 8Monath T P. Dengue and yellow fever--challenges tor the development and use of vaeeines[J]. N Engl J Med, 2007, 357(22) :2222-2225.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部